Argent BioPharma (ASX:RGT) has executed a deed of variation with Mercer Street Global Opportunity Fund to amend the terms of its 2020 convertible securities agreement, according to a Wednesday filing with the Australian bourse.
The adjustment involves refinancing 300,000 convertible notes, worth AU$1.1 million, reducing the minimum conversion price to not less than AU$0.11 from not less than AU$10, the filing said.
The company also plans to negotiate further amendments to the remaining 2020 and 2022 convertible note facilities, the filing added.
Shares of the company fell 6% in recent Wednesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。